Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis.
IMPORTANCE: Commercial epicutaneous peanut immunotherapy (EPIT) and peanut oral immunotherapy (POIT) may offer significant quality-of-life improvements for patients with peanut allergy, but the cost-effectiveness of commercial peanut immunotherapies is uncharacterized. OBJECTIVE: To evaluate critical inputs associated with the cost-effectiveness of EPIT and POIT from a societal perspective. DESIGN, SETTING, AND PARTICIPANTS: Economic evaluation in which microsimulations with Markov modeling were performed evaluating virtual children aged 4 years over an 80-year time horizon. The base-case costs included a caregiver-reported willingness to pay of $3839 annually for safe and effective food allergy treatment. Estimates of predictive biomarkers or oral challenges were incorporated after the first year of therapy with additional analyses of immunotherapy risk reduction of anaphylaxis and probability of sustained unresponsiveness (SU) to peanut after 4 years. EXPOSURES: Children received EPIT, POIT, or no immunotherapy treatment (n = 10 000 per treatment strategy). MAIN OUTCOMES AND MEASURES: Rates of therapy-associated adverse reactions and quality-of-life improvements associated with changes in eliciting or tolerated peanut doses were modeled along with quality-adjusted life-years (QALYs), anaphylaxis, therapy-associated anaphylaxis, and fatalities. RESULTS: In the base-case analysis without SU to peanut, the EPIT strategy cost less than POIT (mean [SD] cost, $154 662 [$46 716] vs $163 524 [$56 800]) and had fewer total episodes of anaphylaxis (mean [SD], 1.33 [1.55] vs 3.83 [5.02] episodes) and fewer episodes of therapy-associated anaphylaxis (mean [SD], 0.62 [1.30] vs 3.10 [4.94] episodes) but had lower QALY accumulation (mean [SD], 26.932 [2.241] vs 26.945 [2.320] QALYs). The incremental cost-effectiveness ratio was $216 061 for EPIT and $255 431 for POIT. Models were sensitive to therapy cost, SU rates, health state utility, and risk reduction of anaphylaxis. With health state utility sensitivity analyses, the ceiling value-based cost (willingness-to-pay threshold $100 000/QALY) was between $1568 and $6568 for EPIT and between $1235 and $5235 for POIT. If high rates of SU to peanut can be achieved in longer-term models, EPIT and POIT could produce savings in terms of both cost and QALY.CONCLUSIONS AND RELEVANCE: In this simulated analysis, findings showed that EPIT and POIT may be cost-effective under some assumptions. Further research is needed to understand the degree of health state utility improvement associated with each therapy, degree of protection against anaphylaxis, and rates of SU.
Proanthocyanidin Interferes with Intrinsic Antibiotic Resistance Mechanisms of Gram‐Negative Bacteria.
Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women.
Mechanisms Underlying the Cardiometabolic Protective Effect of Walnut Consumption in Obese Subjects: A Cross‐Over, Randomized, Double‐Blinded, Controlled Inpatient Physiology Study.
Pistachio consumption modulates DNA oxidation and genes related to telomere maintenance: a crossover randomized clinical trial.
Cranberry Extract May Interfere with Antibiotic Resistance Mechanisms
Researchers have shown that cranberry proanthocyanidin (cPAC) may help potentiate the in vitro activity of a range of antibiotic classes against the human pathogens E. coli, P. mirabilis, and P. aeruginosa. Results from this study also demonstrated that cPAC acts by repressing two antibiotic resistance mechanisms, selective membrane permeability and multidrug efflux pumps (cell transporters). The use of cPAC to potentiate antibiotics and mitigate the development of resistance could improve treatment outcomes and may help to combat the growing threat of antibiotic resistance.
Maisuria, V., Okshevsky, M., Déziel, E., Tufenkji, N. (2019). Proanthocyanidin Interferes with Intrinsic Antibiotic Resistance Mechanisms of Gram‐Negative Bacteria. Advanced Science, doi.org/10.1002/advs.201802333.
Hazelnut consumption improves testicular antioxidant function and semen quality in young and old male rats.
Maternal nut intake in pregnancy and child neuropsychological development up to 8 years old: a population-based cohort study in Spain.
INC World Nut and Dried Fruit Congress
INC Annual Congress is the largest international gathering of food professionals, suppliers, traders and buyers dedicated to the nuts and dried fruits business. From May 11-13, 2022, INC Congress in Dubai will provide a unique environment for participants to learn, do networking and share knowledge and experiences.
- A world-class thought-leadership Conference featuring visionary keynote speakers and panel discussions.
- A cutting-edge product and technology Exhibition featuring the latest trends and products.
- The world’s best venue for seeking industry opportunities, making deals and networking.
- Update on nutrition research studies on health, nuts and dried fruit.
- Update on industry statistics, crop forecasts, supply, consumption and market dynamics.
- Update on scientific food safety and regulations.
- INC Awards Program, highlighting the best of the industry.
- And a varied set of social activities where to renew professional relationship in a different and more relaxed atmosphere. https://nutfruitcongress.org/dubai2022/